Perrigo Company plc Revenue
Perrigo Company plc (PRGO) reported Revenue of $1.02 billion for the 3-month period ending 2026-06-27, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-05
- Perrigo Company plc revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-27 was $1.02B, a 3.17% decline year-over-year.
- Perrigo Company plc revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-28 was $969.20M, a 7.16% decline year-over-year.
- Perrigo Company plc revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $1.11B, a 2.52% decline year-over-year.
- Perrigo Company plc revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-27 was $1.04B, a 4.06% decline year-over-year.
- Perrigo Company plc revenue from contract with customer, excluding assessed tax for fiscal 2025 was $4.25B, a 2.75% decline from fiscal 2024.
- Perrigo Company plc revenue from contract with customer, excluding assessed tax for fiscal 2024 was $4.37B, a 6.06% decline from fiscal 2023.
- Perrigo Company plc revenue from contract with customer, excluding assessed tax for fiscal 2023 was $4.66B, a 4.58% increase from fiscal 2022.
- Perrigo Company plc revenue from contract with customer, excluding assessed tax for fiscal 2022 was $4.45B, a 7.56% increase from fiscal 2021.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 3 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 12 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-27 | $1.02B 10-Q · filed 2026-08-05 | $1.99B 10-Q · filed 2026-08-05 | $3.10B derived: sum of 3 quarters · filed 2026-08-05 | $4.14B derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2026-03-28 | $969.20M 10-Q · filed 2026-05-06 | $2.08B derived: sum of 2 quarters · filed 2026-05-06 | $3.12B derived: sum of 3 quarters · filed 2026-05-06 | $4.18B derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-12-31 | $1.11B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $2.15B derived: sum of 2 quarters · filed 2026-02-26 | $3.21B derived: sum of 3 quarters · filed 2026-08-05 | $4.25B 10-K · filed 2026-02-26 | ||||
| 2025-09-27 | $1.04B 10-Q · filed 2025-11-05 | $2.10B derived: sum of 2 quarters · filed 2026-08-05 | $3.14B 10-Q · filed 2025-11-05 | $4.28B derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-06-28 | $1.06B 10-Q · filed 2026-08-05 | $2.10B 10-Q · filed 2026-08-05 | $3.24B derived: sum of 3 quarters · filed 2026-08-05 | $4.33B derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-03-29 | $1.04B 10-Q · filed 2026-05-06 | $2.18B derived: sum of 2 quarters · filed 2026-05-06 | $3.27B derived: sum of 3 quarters · filed 2026-05-06 | $4.34B derived: sum of 4 quarters · filed 2026-05-06 | ||||
| 2024-12-31 | $1.14B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $2.23B derived: sum of 2 quarters · filed 2026-02-26 | $3.29B derived: sum of 3 quarters · filed 2026-02-26 | $4.37B 10-K · filed 2026-02-26 | ||||
| 2024-09-28 | $1.09B 10-Q · filed 2025-11-05 | $2.15B derived: sum of 2 quarters · filed 2025-11-05 | $3.24B 10-Q · filed 2025-11-05 | $4.39B derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2024-06-29 | $1.07B 10-Q · filed 2025-08-06 | $2.15B 10-Q · filed 2025-08-06 | $3.30B derived: sum of 3 quarters · filed 2026-02-26 | $4.43B derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2024-03-30 | $1.08B 10-Q · filed 2025-05-07 | $2.24B derived: sum of 2 quarters · filed 2026-02-26 | $3.36B derived: sum of 3 quarters · filed 2026-02-26 | $4.56B derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2023-12-31 | $1.16B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $2.28B derived: sum of 2 quarters · filed 2026-02-26 | $3.47B derived: sum of 3 quarters · filed 2026-02-26 | $4.66B 10-K · filed 2026-02-26 | ||||
| 2023-09-30 | $1.12B 10-Q · filed 2024-11-06 | $2.32B derived: sum of 2 quarters · filed 2024-11-06 | $3.50B 10-Q · filed 2024-11-06 | $4.65B derived: sum of 4 quarters · filed 2025-02-28 | ||||
| 2023-07-01 | $1.19B 10-Q · filed 2024-08-02 | $2.37B 10-Q · filed 2024-08-02 | $3.53B derived: sum of 3 quarters · filed 2025-02-28 | $4.63B derived: sum of 4 quarters · filed 2025-02-28 | ||||
| 2023-04-01 | $1.18B 10-Q · filed 2024-05-07 | $2.34B derived: sum of 2 quarters · filed 2025-02-28 | $3.44B derived: sum of 3 quarters · filed 2025-02-28 | $4.56B derived: sum of 4 quarters · filed 2025-02-28 | ||||
| 2022-12-31 | $1.16B derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $2.26B derived: sum of 2 quarters · filed 2025-02-28 | $3.38B derived: sum of 3 quarters · filed 2025-02-28 | $4.45B 10-K · filed 2025-02-28 | ||||
| 2022-10-01 | $1.10B 10-Q · filed 2023-11-07 | $2.22B derived: sum of 2 quarters · filed 2023-11-07 | $3.30B 10-Q · filed 2023-11-07 | $4.40B derived: sum of 4 quarters · filed 2024-02-27 | ||||
| 2022-07-02 | $1.12B 10-Q · filed 2023-08-08 | $2.20B 10-Q · filed 2023-08-08 | $3.30B derived: sum of 3 quarters · filed 2024-02-27 | $4.34B derived: sum of 4 quarters · filed 2024-02-27 | ||||
| 2022-04-02 | $1.07B 10-Q · filed 2023-05-09 | $2.18B derived: sum of 2 quarters · filed 2024-02-27 | $3.22B derived: sum of 3 quarters · filed 2024-02-27 | $4.20B derived: sum of 4 quarters · filed 2024-02-27 | ||||
| 2021-12-31 | $1.10B derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $2.15B derived: sum of 2 quarters · filed 2024-02-27 | $3.13B derived: sum of 3 quarters · filed 2024-02-27 | $4.14B 10-K · filed 2024-02-27 | ||||
| 2021-10-02 | $1.04B 10-Q · filed 2022-11-08 | $2.02B derived: sum of 2 quarters · filed 2022-11-08 | $3.03B 10-Q · filed 2022-11-08 | $4.32B derived: sum of 4 quarters · filed 2022-11-08 | ||||
| 2021-07-03 | $981.10M 10-Q · filed 2022-08-09 | $1.99B 10-Q · filed 2022-08-09 | $3.28B derived: sum of 3 quarters · filed 2022-08-09 | $4.49B derived: sum of 4 quarters · filed 2022-08-09 | ||||
| 2021-04-03 | $1.01B 10-Q · filed 2022-05-11 | $2.30B derived: sum of 2 quarters · filed 2022-05-11 | $3.51B derived: sum of 3 quarters · filed 2022-05-11 | |||||
| 2020-12-31 | $1.29B 10-K · filed 2021-03-01 | $2.50B derived: sum of 2 quarters · filed 2021-03-01 | $4.09B 10-K · filed 2023-02-28 | $5.06B 10-K · filed 2021-03-01 | ||||
| 2020-09-30 | $1.21B 10-K · filed 2021-03-01 | |||||||
| 2020-09-26 | $1.00B 10-Q · filed 2021-11-12 | $1.21B 10-Q · filed 2020-11-05 | $2.22B derived: sum of 2 quarters · filed 2021-11-12 | $3.04B 10-Q · filed 2021-11-12 | $3.77B 10-Q · filed 2020-11-05 | |||
| 2020-06-30 | $1.22B 10-K · filed 2021-03-01 | |||||||
| 2020-06-27 | $948.80M 10-Q · filed 2021-08-11 | $1.22B 10-Q · filed 2020-08-05 | $2.03B 10-Q · filed 2021-08-11 | $2.56B 10-Q · filed 2020-08-05 | ||||
| 2020-03-31 | $1.34B 10-K · filed 2021-03-01 | |||||||
| 2020-03-28 | $1.08B 10-Q · filed 2021-05-12 | $1.34B 10-Q · filed 2020-05-05 | $2.41B derived: sum of 2 quarters · filed 2021-05-12 | $3.60B derived: sum of 3 quarters · filed 2021-05-12 | $4.75B derived: sum of 4 quarters · filed 2021-05-12 | |||
| 2019-12-31 | $1.32B 10-K · filed 2021-03-01 | $2.51B derived: sum of 2 quarters · filed 2021-03-01 | $3.66B derived: sum of 3 quarters · filed 2021-03-01 | $3.87B 10-K · filed 2022-03-01 | $4.84B 10-K · filed 2020-02-27 | |||
| 2019-09-28 | $1.19B 10-K · filed 2021-03-01 | $2.34B derived: sum of 2 quarters · filed 2021-03-01 | $3.51B 10-Q · filed 2020-11-05 | $4.71B derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2019-06-29 | $1.15B 10-K · filed 2021-03-01 | $2.32B 10-Q · filed 2020-08-05 | $3.52B derived: sum of 3 quarters · filed 2021-03-01 | $4.65B derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2019-03-30 | $1.17B 10-K · filed 2021-03-01 | $2.37B derived: sum of 2 quarters · filed 2021-03-01 | $3.50B derived: sum of 3 quarters · filed 2021-03-01 | $4.69B derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2018-12-31 | $1.20B 10-K · filed 2020-02-27 | $2.33B derived: sum of 2 quarters · filed 2020-02-27 | $3.51B derived: sum of 3 quarters · filed 2020-02-27 | $4.73B 10-K · filed 2021-03-01 | ||||
| 2018-09-29 | $1.13B 10-K · filed 2020-02-27 | $2.32B derived: sum of 2 quarters · filed 2020-02-27 | $3.54B 10-Q · filed 2019-11-06 | $4.82B derived: sum of 4 quarters · filed 2020-02-27 | ||||
| 2018-06-30 | $1.19B 10-K · filed 2020-02-27 | $2.40B 10-Q · filed 2019-08-08 | $3.69B derived: sum of 3 quarters · filed 2020-02-27 | $4.92B derived: sum of 4 quarters · filed 2020-02-27 | ||||
| 2018-03-31 | $1.22B 10-K · filed 2020-02-27 | $2.50B derived: sum of 2 quarters · filed 2020-02-27 | $3.73B derived: sum of 3 quarters · filed 2020-02-27 | $4.97B derived: sum of 4 quarters · filed 2020-02-27 | ||||
| 2017-12-31 | $1.28B 10-K · filed 2019-02-27 | $2.51B derived: sum of 2 quarters · filed 2019-02-27 | $3.75B derived: sum of 3 quarters · filed 2019-02-27 | $4.95B 10-K · filed 2020-02-27 | ||||
| 2017-09-30 | $1.23B 10-K · filed 2019-02-27 | $2.47B derived: sum of 2 quarters · filed 2019-02-27 | $3.66B 10-Q · filed 2018-11-08 | |||||
| 2017-07-01 | $1.24B 10-K · filed 2019-02-27 | $2.43B 10-Q · filed 2018-08-09 | ||||||
| 2017-04-01 | $1.19B 10-K · filed 2019-02-27 | |||||||
| 2016-12-31 | $5.28B 10-K · filed 2019-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |